Displaying drugs 101 - 125 of 1617 in total
PF-03814735
PF-03814735 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Name: … PF-03814735 …
Matched Description: … PF-03814735 has been used in trials studying the treatment of Solid Tumors. …
Matched Description: … PF-03814735 has been used in trials studying the treatment of Solid Tumors. …
PF-06459988
PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Investigational
Matched Name: … PF-06459988 …
Matched Description: … PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal …
Matched Description: … PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal …
PF-06815345
PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).
Investigational
Matched Name: … PF-06815345 …
Matched Description: … PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in …
Matched Description: … PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in …
PF-04620110
PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Investigational
Matched Name: … PF-04620110 …
Matched Description: … PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 …
Matched Description: … PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 …
PF-04634817
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
Matched Name: … PF-04634817 …
Matched Description: … Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects). ... PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine …
Matched Description: … Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects). ... PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine …
PF-06700841
PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).
Investigational
Matched Name: … PF-06700841 …
Matched Description: … PF-06700841 in Japanese Healthy Volunteers). ... PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of …
Matched Description: … PF-06700841 in Japanese Healthy Volunteers). ... PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of …
PF-05105679
PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).
Investigational
Matched Name: … PF-05105679 …
Matched Description: … Volunteers Study Of PF-05105679). ... PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy …
Matched Description: … Volunteers Study Of PF-05105679). ... PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy …
PF-05212377
PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).
Investigational
Matched Name: … PF-05212377 …
Matched Description: … PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy ... of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms …
Matched Description: … PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy ... of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms …
VAD-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
Matched Synonyms: … VAD 044 ... VAD-044 …
Matched Name: … VAD-044 …
Matched Description: … VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. …
Matched Name: … VAD-044 …
Matched Description: … VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. …
ELX-02
ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).
Investigational
Matched Name: … ELX-02 …
Matched Description: … ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult …
Matched Description: … ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult …
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Name: … CB-010 …
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
NNC0114-0006
NNC0114-0006 is an anti-interleukin 21 monoclonal antibody
Investigational
Matched Name: … NNC0114-0006 …
Matched Description: … NNC0114-0006 is an anti-interleukin 21 monoclonal antibody …
Matched Description: … NNC0114-0006 is an anti-interleukin 21 monoclonal antibody …
OTX-008
OTX008 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Name: … OTX-008 …
TCB-008
TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.
Investigational
Matched Name: … TCB-008 …
Matched Description: … TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor …
Matched Description: … TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor …
IOWH-032
Iowh032 has been investigated for the treatment of Cholera, Diarrhea, and Secretory Diarrhea.
Investigational
Matched Name: … IOWH-032 …
AGS-005
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
Matched Name: … AGS-005 …
Matched Description: … AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics …
Matched Description: … AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics …
ATU-027
Atu027 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Matched Name: … ATU-027 …
NBL-015
Investigational
Matched Synonyms: … NBL-015 (ANTI-CLAUDIN18.2 MAB) …
Matched Name: … NBL-015 …
Matched Name: … NBL-015 …
CALY-002
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Matched Name: … CALY-002 …
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Name: … Sirna-027 …
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth …
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth …
Displaying drugs 101 - 125 of 1617 in total